Hong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hong Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dan Liu
Cancer Institute Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
1 shared publication - Jibin Liu
Institute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu 226361, P.R. China
1 shared publication Lei Liu
Department of Thoracic Surgery The Affiliated Tumor Hospital of Nantong University Nantong China
1 shared publicationLi Feng
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy for Medical Sciences and Peking Union Medical College Beijing China
1 shared publicationLing Gao
Cancer Institute Longhua Hospital Shanghai University of Traditional Chinese Medicine Shanghai China
1 shared publication- Mingsong Wang
Shanghai Ninth Peoples Hospital, Shanghai Jiaotong University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (60) , e76962
Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma
The importance of fibrillarin (FBL), an established nucleolar methyltransferase, was identified in neoplastic growth of esophageal squamous cell carcinoma (ESCC), one of the most lethal malignancies worldwide. However, the underlying mechanism remains unclear. Here, by enrolling independent ESCC cohorts, we verified the negative correlation between intratumoral FBL expression and patient prognosis. Notably, comprehensive transcriptomic and metabolomic analyses indicated that FBL deletion elicited cell cycle arrest and cellular senescence, as well as block of nicotinamide metabolism and increase of oxidative stress. Mechanistically, FBL could bind to and stabilize SIRT1 by obstructing the ubiquitin‐proteasome‐mediated protein degradation, therefore provoking nicotinamide metabolism, sustaining redox homeostasis, and counteracting senescence. Clinically, FBL‐SIRT1 axis was augmented in tumor tissues of ESCC patients, and high intratumoral SIRT1 expression predicted poor patient survival. Finally, we found that both genetic and pharmacological inhibition of FBL could sensitize senolytic therapy for ESCC. In conclusion, we first discovered FBL as an anti‐senescent protein in tumor progression. FBL resists cellular senescence by stabilizing SIRT1 and sustaining the nicotinamide metabolism, therefore providing an optional strategy for ESCC treatment by sensitizing senolytic therapy with FBL inhibitors.
- 10 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (60) , e76962
Open AccessFibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma
The importance of fibrillarin (FBL), an established nucleolar methyltransferase, was identified in neoplastic growth of esophageal squamous cell carcinoma (ESCC), one of the most lethal malignancies worldwide. However, the underlying mechanism remains unclear. Here, by enrolling independent ESCC cohorts, we verified the negative correlation between intratumoral FBL expression and patient prognosis. Notably, comprehensive transcriptomic and metabolomic analyses indicated that FBL deletion elicited cell cycle arrest and cellular senescence, as well as block of nicotinamide metabolism and increase of oxidative stress. Mechanistically, FBL could bind to and stabilize SIRT1 by obstructing the ubiquitin‐proteasome‐mediated protein degradation, therefore provoking nicotinamide metabolism, sustaining redox homeostasis, and counteracting senescence. Clinically, FBL‐SIRT1 axis was augmented in tumor tissues of ESCC patients, and high intratumoral SIRT1 expression predicted poor patient survival. Finally, we found that both genetic and pharmacological inhibition of FBL could sensitize senolytic therapy for ESCC. In conclusion, we first discovered FBL as an anti‐senescent protein in tumor progression. FBL resists cellular senescence by stabilizing SIRT1 and sustaining the nicotinamide metabolism, therefore providing an optional strategy for ESCC treatment by sensitizing senolytic therapy with FBL inhibitors.